Search Results for “Customizable SAP E_S4HCON2023 Practice Exam Software 🐂 Easily obtain ➠ E_S4HCON2023 🠰 for free download through ⇛ www.pdfvce.com ⇚ 🛐E_S4HCON2023 Exam Practice” – Page 27

Diagnosis of urticaria

74.	Schoepke, N., Doumoulakis, G., and Maurer, M.: Diagnosis of urticaria. Ind. J. Dermatology 2013: 58; 211-218. IF: N/A

155	Cai, Y., Folkerts, J., Folkerts, G., Maurer, M., and Braber, S.+: Microbiota-dependent and –independent effects of dietary fiber on human health. Brit. J. Pharmacol. 2020: 177; 1363-1381. IF: 8.74

r.155

73.	Maurer, M. and Parish, L. C.: The dermatology view of hereditary angioedema: Practical diagnostic and management considerations. J. Eur. Acad. Dermatol. Venereol. 2013: 27; 133-141. IF: 2.78

61	Siebenhaar, F., Magerl, M., Peters, E. M. J., Hendrix, S., Metz, M., and Maurer, M.+: Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J. Allergy Clin. Immunol. 2008: 121; 955-961. IF: 9.77

154	Kolkhir, P., Altrichter, S., Muñoz, M., Hawro, T., and Maurer, M.+: New treatments for chronic urticaria. Ann. Allergy Asthma Immunol. 2020: 124; 2-12. IF: 6.35

r.154

From seafood waste to active seafood packaging: an emerging opportunity of the circular economy

149

De la Caba, K., Guerrero, P., Si Trung, T., Cruz-Romero, M., Kerry, J. P., Fluhr, J., Maurer, M., Kruijssen, F., Albalat, A., Bunting, S., Burt, S., Little, D., and Newton, R.: From seafood waste to active seafood packaging: an emerging opportunity of the circular economy. J. Clean. Prod. 2019: 208; 86-98. IF: 7.25

r.149

Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study

173

Bas, M.+, Greve, J., Hoffmann, T., Reshef, A., Aberer, W., Maurer, M. Kivity, S., Farkas, H., Floccard, B., Arcoleo, F., Martin, L., Sitkauskiene, B., Bouillet, L., Schmid-Grendelmeier, P., Li, H., and Zanichelli, A.: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013: 68; 1452-1459. IF: 5.99

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines

411.

Agache, I.⁺, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.*, Palomares, O.*, and Jutel, M.*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 45-58. IF: 14.71

o.411

Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria

174

Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J. C., Staubach, P., Wedi, B., Weidner, C., and Maurer, M.+: Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2013: 27; e363-e369. IF: 2.78

146	Maurer, M.+, Taube, C., Schröder, N. W. J., Ebmeyer, J., Siebenhaar, F., Geldmacher, A., Schubert, N., and Roers, A.+: Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. J. Allergy Clin. Immunol. 2019: 4; S19-30. IF: 10.23

Results